Chardan Capital reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. Chardan Capital currently has a $14.00 price objective on the stock.
Coya Therapeutics Trading Down 3.6 %
Shares of Coya Therapeutics stock opened at $8.72 on Monday. The company has a fifty day moving average price of $9.22 and a 200 day moving average price of $7.21. Coya Therapeutics has a twelve month low of $3.21 and a twelve month high of $10.69. The stock has a market cap of $127.31 million, a price-to-earnings ratio of -11.18 and a beta of 0.80.
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last issued its earnings results on Tuesday, March 19th. The company reported $0.15 earnings per share for the quarter. The company had revenue of $6.00 million during the quarter.
Institutional Inflows and Outflows
Coya Therapeutics Company Profile
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Featured Articles
- Five stocks we like better than Coya Therapeutics
- How to Calculate Inflation Rate
- AMD is Down 35%. Now is the Time to Buy the Dip
- What is Put Option Volume?
- Amazon Stands Tall: New Highs Are in Sight
- Stock Market Upgrades: What Are They?
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.